Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 188-198, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-157868
ABSTRACT
Over the past decade, several kinase inhibitors have been approved based on their clinical benefit in cancer patients. Unfortunately, in many cases, patients develop resistance to these agents via secondary mutations and alternative mechanisms. To date, several major mechanisms of acquired resistance, such as secondary mutation of the epidermal growth factor receptor (EGFR) gene, amplification of the MET gene and overexpression of hepatocyte growth factor, have been reported. This review describes the recent findings on the mechanisms of primary and acquired resistance to EGFR tyrosine kinase inhibitors and acquired resistance to anaplastic lymphoma kinase inhibitors, primarily focusing on non-small cell lung carcinoma.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fosfotransferases
/
Proteínas Tirosina Quinases
/
Resistência a Medicamentos
/
Fator de Crescimento de Hepatócito
/
Receptores Proteína Tirosina Quinases
/
Inibidores de Proteínas Quinases
/
Fator de Crescimento Epidérmico
/
Receptores ErbB
/
Pulmão
/
Linfoma
Limite:
Humanos
Idioma:
Inglês
Revista:
Tuberculosis and Respiratory Diseases
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS